¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary receptor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary hemorrhage
    ¼Ó¹ßÃâÇ÷, ÀÌÂ÷ÃâÇ÷
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • secondary hypogonadism
    ¼Ó¹ß»ý½Ä»ùÀúÇÏÁõ, ¼Ó¹ß»ý½Ä¼±ÀúÇÏÁõ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • secondary keratitis
    ¼Ó¹ß°¢¸·¿°
  • secondary lysosome
    ÀÌÂ÷¿ëÇØ¼Òü
  • secondary nodule
    Á¾ÀÚÁß½É, ¹èÁß½É
  • secondary pneumonia
    ¼Ó¹ßÆó·Å
  • secondary process thinking
    ÀÌÂ÷°úÁ¤»ç°í
  • secondary sequestrum
    ÀÌÂ÷ºÎ°ñ, ºÎºÐºÐ¸®Á×Àº»À
  • secondary sex characteristic
    ÀÌÂ÷¼ºÂ¡
  • secondary sexual character
    ÀÌÂ÷¼ºÂ¡
  • secondary shock
    ÀÌÂ÷¼îÅ©, ¼Ó¹ß¼îÅ©
  • secondary sterility
    ¼Ó¹ßºÒÀÓ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary infection
    ÀÌÂ÷°¨¿°
  • secondary keratitis
    ¼Ó¹ß°¢¸·¿°
  • secondary nodule
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
  • secondary pneumonia
    ¼Ó¹ßÆó·Å
  • secondary attack rate
    ÀÌÂ÷¹ßº´·ü
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • secondary
    ÀÌÂ÷-, Á¦ÀÌ-, ¼Ó¹ß-
  • secondary sequestrum
    ºÎºÐºÐ¸®Á×Àº»À, Á¦À̱âºÎ°ñ
  • secondary shock
    ÀÌÂ÷¼îÅ©
  • secondary sterility
    ÀÌÂ÷ºÒÀÓ(Áõ)
  • secondary suture
    ÀÌÂ÷ºÀÇÕ
  • secondary process thinking
    ÀÌÂ÷°úÁ¤»ç°í
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ¾Èµå·Î°Õ¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Kainate amino acid receptor
    Ä«À̳×ÀÌÆ® ¾Æ¹Ì³ë»ê ¼ö¿ëü(áôé»ô÷)
  • Kinesthetic receptor
    ¿îµ¿(ê¡ÔÑ)(°¨(Êï))°¢¼ö¿ëü(ÊÆáôé»ô÷)
  • NMDA receptor
    ¿£¾Úµð¿¡ÀÌ ¼ö¿ëü
  • T cell receptor
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ³²¼ºÈ£¸£¸ó ¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • beta adrenergic receptor
    º£Å¸¾Æµå·¹³¯¸°¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼öü)
  • beta receptor
    º£Å¸ ¼ö¿ëü(¼ö¿ë±â, °¨¼öü, °¨¼ö±â)
  • beta receptor blocker
    º£Å¸¼ö¿ëü Â÷´ÜÁ¦( -áôé»ô÷ ó´Ó¨ð¥)
  • beta receptor stimulating agent
    º£Å¸¼ö¿ëü ÀÚ±ØÁ¦( -áôé»ô÷ í©Ð½ð¥)
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • beta-adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü
  • cardiac receptor
    ½ÉÀå¼ö¿ëü(ãýíôáôé»ô÷)
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°(ÀÛµ¿)¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • cold receptor
    ³Ã°¢¼ö¿ëü(Ò²ÊÆáôé»ô÷)(¼ö¿ë±â, °¨¼ö±â)
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement receptor 1
    º¸Ã¼ ¼ö¿ëü 1
  • complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • complement receptor 3
    º¸Ã¼¼ö¿ëü 3
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Secondary osteogenic bud
    ÀÌÂ÷»À¹ß»ý½Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñÇü¼º¾Æ
  • Secondary ossification center
    ÀÌÂ÷»À¹ß»ýÁß½É
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñÈ­Áß½É
  • Secondary ossification center [Epiphyseal ossification cente
    ÀÌÂ÷»À¹ß»ýÁ᫐ [»À³¡»À¹ß»ýÁß½É]
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñÈ­Áß½É
  • Secondary bone trabecula
    ÀÌÂ÷»ÀÀܱâµÕ
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ¼ÒÁÖ
  • Secondary dentin
    ÀÌÂ÷»ó¾ÆÁú
    [¿¾ ¿ë¾î] ÀÌÂ÷»ó¾ÆÁú
  • Secondary nodule
    ÀÌÂ÷¼ÒÀý
    [¿¾ ¿ë¾î] ÀÌÂ÷¼ÒÀý
  • Secondary villus
    ÀÌÂ÷À¶¸ð
    [¿¾ ¿ë¾î] ÀÌÂ÷À¶¸ð
  • Secondary pregnancy
    ÀÌÂ÷ÀÓ½Å
    [¿¾ ¿ë¾î] ÀÌÂ÷ÀÓ½Å
  • Secondary spermatocyte
    ÀÌÂ÷Á¤¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷Á¤¸ð¼¼Æ÷
  • Secondary spermatocyte
    ÀÌÂ÷Á¤¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] Á¦ÀÌÁ¤¸ð¼¼Æ÷
  • Secondary nasal septum
    ÀÌÂ÷ÄÚÁß°Ý
    [¿¾ ¿ë¾î] ÀÌÂ÷ºñÁß°Ý
  • Secondary hair follicle
    ÀÌÂ÷ÅÐÁÖ¸Ó´Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷¸ð³¶
  • Secondary sponge bone
    ÀÌÂ÷ÇØ¸é»À
    [¿¾ ¿ë¾î] ÀÌÂ÷ÇØ¸é°ñ
  • Secondary pulmonary lobule
    ÀÌÂ÷ÇãÆÄ¼Ò¿±
    [¿¾ ¿ë¾î] ÀÌÂ÷Æó¼Ò¿±
  • Palatine process [Secondary palate]
    ÀÔõÀåµ¹±â [ÀÌÂ÷ÀÔõÀå]
    [¿¾ ¿ë¾î] ±¸°³µ¹±â(ÀÌÂ÷±¸°³)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary lysosome
    ÀÌÂ÷(ì£ó­) ¶óÀ̼ҼØ
  • secondary malnutrition
    ÀÌÂ÷ ¿µ¾ç½ÇÁ¶(ì£ó­ç½å×ã÷ðà)
  • secondary messenger
    ÀÌÂ÷ Àü·É (ì£ó­îîÖµ)
  • secondary metabolite
    ÀÌÂ÷ ´ë»ç¹°(ì£ó­ÓÛÞóÚª)
  • secondary plant constituent
    ÀÌÂ÷ ½Ä¹°¼ººÐ(ì£ó­ãÕÚªà÷ÝÂ)
  • secondary plot
    ÀÌÂ÷(ì£ó­) Ç÷Ô
  • secondary protein derivative
    ÀÌÂ÷ ´Ü¹éÁúÀ¯µµÃ¼(ì£ó­Ó±ÛÜòõë¯Óôô÷)
  • secondary solvent
    ÀÌÂ÷ ¿ë¸Å(ì£ó­éÁØÚ)
  • secondary standard
    ÀÌÂ÷ Ç¥ÁØ(ì£ó­øöñÞ)
  • secondary structure
    ÀÌÂ÷ ±¸Á¶(ì£ó­Ï°ðã)
  • super-secondary structure
    ÃÊÀÌÂ÷ ±¸Á¶(õ±ì£ó­Ï°ðã)
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HSH hypomagnesemia with secondary hypocalcemia
HSRD hypertension secondary to renal disease
LSSA lipid-soluble secondary antioxidant
PRICES protection, rest, ice, compression, elevation, support [primary treatment of tendinitis and overuse ...
SACS secondary anticoagulation system
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SIMS Secondary ion mass spectroscopy
SP Secondary progressive
ToF-SIMS Time of Flight Secondary Ion Mass Spectrometry
SE secondary electron
SHPT secondary hyperparathyroidism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • secondary herpes simplex
    ÀÌÂ÷Àû ±¸¼ø Æ÷Áø
  • secondary hyperalgesia
    ¼Ó¹ß¼º Åë°¢ °ú¹Î, ÀÌÂ÷Àû Åë°¢ °ú¹Î
    µ¿ÀǾî=secondary hy
  • secondary hyperparathyroidism
    ¼Ó¹ß¼º ºÎ°©»ó¼± ±â´É Ç×Áø, ¼Ó¹ß¼º ºÎ°©»ó¼± ±â´É Ç×ÁøÁõ
  • secondary hypertrophic osteoarthropathy
    ¼Ó¹ß¼º ºñ´ë¼º °ñ °üÀýº´Áõ
  • secondary impression
    ÀÌÂ÷ Àλó
  • secondary inoculation
    ÀÌÂ÷ Á¢Á¾
  • secondary lesion
    ÀÌÂ÷¼º º´º¯, ÀÌÂ÷ ¹ßÁø, ¼Ó¹ßÁø
  • secondary local muscle soreness
    ¼Ó¹ß¼º ±¹¼Ò ±Ùµ¿Åë
  • secondary occlusal trauma
    ¼Ó¹ß¼º ±³ÇÕ ¿Ü»ó
    ÀÌ¹Ì Ä¡ÁÖ ÁúȯÀÌ ÀÖ´Â Ä¡¾Æ¿¡ °¡ÇØÁø °úµµÇÑ ±³ÇÕ·ÂÀ¸·Î ÀÎÇÑ Ä¡ÁÖ Á¶Á÷ÀÇ ¿Ü»ó.
  • secondary ossification center
    ÀÌÂ÷ °ñÈ­ Áß½É
  • secondary osteon
    ÀÌÂ÷ »À ´ÜÀ§
  • secondary pain
    ¼Ó¹ß¼º ÅëÁõ, Á¦ÀÌ µ¿Åë
    µ¿ÀǾî=referred
  • secondary palate
    ÀÌÂ÷ ±¸°³
  • secondary pathway
    ÀÌÂ÷ °æ·Î
  • secondary pneumonia
    ¼Ó¹ß¼º Æó·Å
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
gene rearrangement, delta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, gamma-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
(12 Dec 1998)
genes, T-cell receptor DNA sequences, in cells of the t-lymphocyte lineage, that code for T-cell receptors. The tcr genes are formed by somatic rearrangement (see gene rearrangement, t-lymphocyte and its children) of germline gene segments, and resemble ig genes in their mechanisms of diversity generation and expression.
(12 Dec 1998)
genes, T-cell receptor alpha DNA sequences encoding the alpha chain of the T-cell receptor. The genomic organization of the tcr alpha genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor beta DNA sequences encoding the beta chain of the T-cell receptor. The genomic organization of the tcr beta genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor delta DNA sequences encoding the delta chain of the T-cell receptor. The delta-chain locus is located entirely within the alpha-chain locus.
(12 Dec 1998)
genes, T-cell receptor gamma DNA sequences encoding the gamma chain of the T-cell receptor. The human gamma-chain locus is organised similarly to the tcr beta-chain locus.
(12 Dec 1998)
receptor 1. A molecular structure within a cell or on the surface characterised by selective binding of a specific substance and a specific physiologic effect that accompanies the binding, for example, cell surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments and immunoglobulins and cytoplasmic receptors for steroid hormones.
2. A sensory nerve terminal that responds to stimuli of various kinds.
(18 Nov 1997)
receptor aggregation Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell.
(12 Dec 1998)
receptor agonist A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted.
(22 May 1997)
receptor-CD3 complex, antigen, T-cell Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex.
(12 Dec 1998)
receptor, chemokine A molecule that receives a chemokine and acts as a dock for a chemokine. Several chemokine receptors are essential co-receptors for HIV.
(12 Dec 1998)
receptor downregulation A phenomenon observed in many cells: following stimulation with a ligand the number of receptors for that ligand on the cell surface diminishes because internalisation exceeds replenishment. Often used very loosely, thus destroying the utility of the term.
(18 Nov 1997)
receptor mediated endocytosis Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route.
(18 Nov 1997)
receptor potential The transmembrane potential difference of a sensory cell. Such cells are not generally excitable, but their response to stimulation is a gradual change in their resting potential.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á